References
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
- Muiesan ML, Salvetti M, Rizzoni D, et al. Resistant hypertension and target organ damage. Hypertens Res. 2013;36(6):485–491.
- Daugherty SL, Powers DJ, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–1642.
- Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68(2):297–306.
- Eskås PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016;25(4):199–205.
- Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension. 2022;79(1):e1–e14.
- Lane D, Lawson A, Burns A, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension. 2022;79(1):12–23.
- Wunder C, Persu A, Lengelé J-P, et al. Adherence to antihypertensive drug treatment in patients with apparently treatment-resistant hypertension in the INSPiRED pilot study. Blood Press. 2019;28(3):168–172.
- Pappaccogli M, Di Monaco S, Georges CMG, et al. Predictors of blood pressure control in patients with resistant hypertension after intensive management in two expert centres: the Brussels-Torino experience. Blood Press. 2019;28(5):336–344.
- Judd E, Calhoun DA, Judd E, et al. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014;28(8):463–368.
- Maw AM, Thompson LE, Ho PM, et al. Implications of guideline updates for the management of apparent treatment resistant hypertension in the United States (a NCDR research to practice [R2P] project). Am J Cardiol. 2020;125(1):63–67.
- Petit G, Berra E, Georges CMG, et al. Impact of psychological profile on drug adherence and drug resistance in patients with apparently treatment-resistant hypertension. Blood Press. 2018;27(6):358–367.
- Kellner S. Theories and research. J Nerv Ment Dis. 1990;178(3):150–160.
- Stergiou GS, Palatini P, Parati G, et al. 2021 European society of hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293–1302.
- O'Brien E, Parati G, Stergiou G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731–1768.
- Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–774.
- Gross JJ, John OP. Individual differences in two emotion regulation processes: implication for affect, relationships and well-being. J Pers Soc Psychol. 2003;85(2):348–362.
- Ioannidis CA, Siegling AB. Criterion and incremental validity of the emotion regulation questionnaire. Front Psychol. 2015;6:247.
- Cutuli D. Cognitive reappraisal and expressive suppression strategies role in the emotion regulation: an overview on their modulatory effects and neural correlates. Front Syst Neurosci. 2014;8:175.
- Garnefski N, Legerstee J, Kraaij VV, et al. Cognitive coping strategies and symptoms of depression and anxiety: a comparison between adolescents and adults. J Adolesc. 2002;25(6):603–611.
- Garnefski N, Kraaij V, Spinhoven P. Negative life events, cognitive emotion regulation and emotional problems. Personal Individ Differ. 2001;30(8):1311–1327.
- Bagby RM, Parker JDA, Taylor GJ. The twenty-item toronto alexithymia Scale-I. Item selection and cross-validation of the factor structure. J Psychosom Res. 1994;38(1):23–32.
- Derogatis LR. Brief symptom inventory: BSI; administration, scoring, and procedures manual. Minneapolis, MN: Pearson; 1993.
- Foa EB, Cashman L, Jaycox L, et al. The validation of a self-report measure of posttraumatic stress disorder: the posttraumatic diagnostic scale. Psychol Assess. 1997;9(4):445–451.
- Bowerman O. Linear statistical models. Thomson Q2 Wadsworth, Belmond (California); 1990.
- de Jager RL, van Maarseveen EM, Bots ML, et al. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018;84(1):18–24.
- Gupta P, Patel P, Strauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69(6):1113–1120.
- Casagrande M, Mingarelli A, Guarino A, et al. Alexithymia: a facet of uncontrolled hypertension. Int J Psychophysiol. 2019;146:180–189.
- Bailey PE, Henry JD. Alexithymia, somatization and negative effects in a community sample. Psychiatry Res. 2007;150(1):13–20.
- Mattila AK, Kronholm E, Jula A, et al. Alexithymia and somatization in general population. Psychosom Med. 2008;70(6):716–722.
- Liu L, Cohen S, Schulz MS, et al. Sources of somatization: exploring the roles of insecurity in relationships and styles of anger experience and expression. Soc Sci Med. 2011;73(9):1436–1443.
- Raffagnato A, Angelico C, Valentini P, et al. Using the body when there are no words for feelings: alexithymia and somatization in self-harming adolescents. Front Psychiatry. 2020;11:262.
- Burnier M, Wuerzner G, Struijker-Boudier H, et al. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62(2):218–225.
- Bapolisi A, Maurage P, Pappaccogli M, et al. Association between post-traumatic stress disorder and hypertension in congolese exposed to violence: a case-control study. J Hypertens. 2022;40(4):685–691.